Coegin Pharma har en solid patentportfölj med 21 patentfamiljer inkluderande substanspatent, användarpatent, kombinationspatent och formuleringspatent. Patentfamiljerna i tabellen nedan har lämnats in i USA, Europa, Kanada, Japan, Australien och även i andra områden som Kina, Hongkong, Korea, Indien, Israel, Nya Zeeland och Norge.
Utvalda patentfamiljer |
|
Novel compositions and uses thereof |
PCT/GB2012/051955 |
Peptides for treatment of diabetes |
PCT/EP2018/061547 |
Peptides fragments for treatment of diabetes |
PCT/EP2019/080563 |
Topical formulation of FOL005 |
PCT/EP2020/061453 |
Peptides for use in skin and hair pigmentation |
PCT/EP2021/080032 |
AVX001/AVX002 type compounds – treatment of psoriasis
|
PCT/GB03/000364 |
AVX001 type ketones for the treatment of glomerulonephritis |
PCT/EP2010/003384 |
Oxothiazole compounds and their use for the treatment of certain chronic inflammatory conditions |
PCT/2010/064687 |
Oxothiazole compounds and their use in the treatment of chronic inflammatory disorders and proliferative disorders such as cancer |
PCT/EP2014/051655 |
Oxothiazole compounds and their use for the treatment of chronic inflammatory disorders and proliferative disorders such as cancer |
PCT/EP2015/067836 |
AVX001 type ketones for the treatment of skin cancer |
PCT/EP2015/061534 |
AVX001 and AVX002 in combination with BEZ235 |
PCT/EP2017/056022 |
AVX235 and AVX420 in combination with BEZ235 |
PCT/EP2017/056016 |
Formulation comprising AVX001 type ketones and silicone |
PCT/EP2017/073951 |
Oxothiazole compounds in combination with a secosteroid |
PCT/EP2017/078169 |
Oxothiazole compounds in combination with a corticosteroid |
PCT/EP2017/078162 |
AVX001 type ketones for the treatment of fibrotic diseases |
PCT/EP2018/066028 |
Oxothiazole compounds for the treatment of fibrotic diseases |
PCT/EP2019/060544 |
AVX001/AVX002 type compounds for use in the prevention of metastasis in cancer |
PCT/EP2020/071168 |
Novel compositions and uses thereof |
PCT/GB2012/051955 |
Peptides for treatment of diabetes |
PCT/EP2018/061547 |